FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL							
	3235-0287							
	Estimated average burden							
l	hours per response:	0.5						

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

4. Names and		D*				. ,		ker or Tradin		01 1340	5.5	Pelationshin	of Reporting	Person(s) to Iss	uer	
1. Name and Address of Reporting Person* NIFFENEGGER KATHI						2. Issuer Name and Ticker or Trading Symbol Stellar Biotechnologies, Inc. [SBOTF]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
													(give title	Other (s	· .	
(Last) (First) (Middle) C/O STELLAR BIOTECHNOLOGIES, INC.						3. Date of Earliest Transaction (Month/Day/Year) 11/12/2014							Chief Financial Officer			
	T SCOTT S		-,													
(Street)			4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
PORT	C	A	93041									X Form filed by One Reporting Person				
HUENEI	ME 											Form f Persor		than One Repo	rting	
(City)	(Si	tate)	(Zip)													
		Tab	le I - Non-I	Derivati	ve Se	curities	s Ac	quired, D	isposed (of, or Be	neficial	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Year) i	2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		Beneficia Owned F	es Form ally (D) o Following (I) (Ir	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	mount (A) or (D)		Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
		٦	Table II - De					uired, Dis , options				Owned				
1. Title of Derivative Security (Instr. 3)	Conversion Date Executor Exercise (Month/Day/Year) if any		3A. Deemed Execution Dat if any (Month/Day/Ye	Date, Transaction Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	· v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right To Buy)	\$1.3439 ⁽¹⁾	11/12/2014		A		90,000		(2)	11/12/2021	Common Shares	90,000	\$0	90,000	D		

Explanation of Responses:

1. The options are exercisable at a price of C\$1.52. The U.S. dollar price reported on this Form 4 in column 2 reflects the U.S. dollar equivalent exercise price on the date of grant, calculated at the closing price for cable transfers in Canadian dollars as reported by Bloomberg on such date of U.S.\$1.00 = CDN\$1.1311.

2. One-third of the option vested immediately, one-third of the option vests on the first anniversary of November 12, 2014, and one-third of the option vests 18 months after November 12, 2014.

Kathi Niffenegger

** Signature of Reporting Person Date

11/13/2014

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.